A meta-analyses of various multigene breast cancer signatures, including the 70-gene NKI (MammaPrint) profile[9], the MS-14[10], EMC-76[11], CSR/wound-response[12], Oncotype Recurrence Score[13], p53[14] and the genomic grade index[15], concluded that their prognostic values are comparable when evaluated in HRpos breast cancers, presumably due to the fact that the proliferation modules within these diverse gene signatures are a common driving force behind their overall prognostic performance[16,17]. This evidence concerns the gene TP53 and breast cancer.